Results 251 to 260 of about 1,184,096 (322)

Leader-Follower Consensus Protocol for a Class of Nonlinear Multi-Agent Systems

Mukai Zhang, Badriah Alsirhan, Vijay Gupta, Stefen Hui, Stanisław H. Żak   +4 more
openalex   +1 more source

Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework

Advanced Science, EarlyView.
In this work, we showcased two significant scientific advances in (i) developing a portable biosensor technology for rapid decentralized prostate cancer urinary biomarker testing and reporting, with superior performance to current clinical testing practice; and (ii) proposing a clinical validation framework (for our biosensor development) which can be ...
Kevin M. Koo, Grant Phillips, Sriganesh Srihari, Áine Farrell, Binny Jaradi, Kira J. Fitzpatrick, John W. Yaxley, Hemamali Samaratunga, Paul N. Mainwaring, Ke‐lin Ru, Darren J. Korbie, Scott A. Tomlins, Matthew J. Roberts, Robert A. Gardiner, Matt Trau   +14 more
wiley   +1 more source

Agreement testing of AMSTAR-PF, a tool for quality appraisal of systematic reviews of prognostic factor studies. [PDF]

BMJ Open
Henry ML, O'Connell NE, Riley RD, Moons KGM, Shea BJ, Hooft L, Wallwork SB, Damen JAAG, Skoetz N, Appiah RP, Berryman C, Crouch SM, Ferencz GA, Grant AR, Henry KM, Herman AM, Karran EL, Koralegedera I, Leake HB, MacIntyre E, Mouatt B, Phuentsho K, Van Der Laan DA, Welsby E, Wiles LK, Wilkinson EM, Wilson MK, Wilson MV, Moseley GL.   +28 more
europepmc   +1 more source

mellington194/lacp-specification: LACP v1.0.0: Transport, Semantic & Consensus Protocol Standard

mellington194
openalex   +1 more source

Olfactory‐to‐Entorhinal Network Dysrhythmias Drive Parkinson's Cognitive Impairment Through Frequency‐Specific Oscillatory Decoupling

Advanced Science, EarlyView.
Wang et al reveal that in the olfactory system, the selective impairment of gamma‐driven Barcode features underlying early olfactory deficits, while the selective impairment of theta‐driven Barcode features underlying later cognitive deficits, further establishing cross‐network gamma oscillations in the early stage as a biomarker of later cognitive ...
Shuaishuai Wang, Zhishen Cai, Xingfeng Mao, Yixuan Zhang, Yunlong Pan, Jiawen Cheng, Xuechun Wang, Hengyi Song, Sasaki Takuya, Ming Lu, Gang Hu, Xiuxiu Liu, Yingmei Lu, Feng Han   +13 more
wiley   +1 more source

Protocol for the development of a Core Outcome Set (COS) for reporting outcomes of clinical trials of anti-tuberculosis treatment in adults with pulmonary tuberculosis. [PDF]

Trials
Thomas R, Harman NL, Williamson PR, Bonnett L, Davies GR, TB-COS Steering Committee.   +5 more
europepmc   +1 more source

General and efficient decentralized consensus protocols II

, 1988
Jean‐Claude Bermond, Jean‐Claude König   +1 more
openalex   +1 more source

CLinNET: An Interpretable and Uncertainty‐Aware Deep Learning Framework for Multi‐Modal Clinical Genomics

Advanced Science, EarlyView.
Identifying disease‐causing genes in neurocognitive disorders remains challenging due to variants of uncertain significance. CLinNET employs dual‐branch neural networks integrating Reactome pathways and Gene Ontology terms to provide pathway‐level interpretability of genomic alterations.
Ivan Bakhshayeshi, Mohammad Mahdi Hosseini, Ahmadreza Argha, Roxana Zahedi, Nigel H. Lovell, Hamid Alinejad‐Rokny   +5 more
wiley   +1 more source

Co-Design of a Registry-Based Tailored Follow-up Service Intervention for People Living With Stroke: A Multiple Method Consensus Approach. [PDF]

Health Expect
Purvis T, Ross AG, Blennerhassett JM, Barclay KM, Frost T, Wong D, Hillier S, Bagot KL, Kim J, Cranefield J, Jaques K, Nelson MR, Russell G, Scott C, Stirling M, Kilkenny MF, Lannin NA, Kleinig TJ, Grimley RS, Morrison JL, Middleton S, Thijs V, Gibbs AK, Cadilhac DA, A‐LISTS investigator group.   +24 more
europepmc   +1 more source

Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer

Advanced Science, EarlyView.
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu, Keda Yu, Lei Liu, Qin Wang, Xiaohui Wu, Yihai Chen, Guozheng Li, Xin Zhang, Bo Wei, Zitong Fu, Abiyasi Nanding, Zuxianglan Zhao, Lingbing Yang, Xingda Zhang, Jianyu Wang, Wantong Sun, Yi Hao, Zhongyi Cheng, Xiaojiang Cui, Hao Wu, Da Pang   +20 more
wiley   +1 more source